Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
The early diagnosis of Sézary syndrome (SS) is challenging. Loss of CD7 and CD26 expression on CD4+ T cells is the currently used criterion in the initial diagnosis and staging of patients with SS. Our aim was to evaluate the respective value of CD26, CD7 and KIR3DL2 expression on CD4+ T cells and total lymphocytes at initial diagnosis of SS. This prospective study included 254 patients with clinical features consistent with cutaneous T-cell lymphoma seen at our institution between March 2014 and February 2019. Peripheral blood analysis by flow cytometry was performed for each patient at the time of diagnosis and during follow-up. The diagnosis of SS was based on ISCL/EORTC criteria. The presence of KIR3DL2+ Sézary cells (SCs) ≥ 200 μL-1 correlated with the diagnosis of SS, with sensitivity of 88·6% and specificity of 96·3%. All 154 patients with either inflammatory skin disease or other haematological disease had KIR3DL2+ cells < 200 μL-1 , while eight of them had CD4+ CD26- T cells ≥ 1000 μL-1 . Of five patients with SS and lymphopenia, four had CD4+ CD7- T cells < 1000 μL-1 and three had CD4+ CD26- T cells < 1000 μL-1 . However, all of them had KIR3DL2+ CD4+ T cells ≥ 200 μL-1 . Among patients with available samples during evolution, all B1-staged patients with ≥ 200 μL-1 KIR3DL2+ SCs at diagnosis evolved to B2 stage within 7 months. KIR3DL2 expression on T cells is highly specific and helps the early diagnosis of SS, especially in those patients with lymphopenia.